Novo Nordisk’s Q3 top-line numbers are healthy and met expectations but profitability fell short. With a local currency (LC) growth of 5% and a negative FX impact of 1%, sales came in at DKK27.76bn. NB All sales growth numbers in LC unless specified otherwise. Growth was solely driven by diabetes and obesity (+6%) sales of DKK23.37bn, making up for the flat performance of the biopharma business to DKK4.40bn. There was no respite for insulins (-2%) during the quarter, with the pressure i
05 Nov 2018
Q3 characterised by insulin disappointment, GLP-1 strength and restructuring-led profit miss
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q3 characterised by insulin disappointment, GLP-1 strength and restructuring-led profit miss
Novo Nordisk A/S Class B (NNO2:WBO) | 0 0 2.2% | Mkt Cap: 611,927m
- Published:
05 Nov 2018 -
Author:
Kamla Singh -
Pages:
3
Novo Nordisk’s Q3 top-line numbers are healthy and met expectations but profitability fell short. With a local currency (LC) growth of 5% and a negative FX impact of 1%, sales came in at DKK27.76bn. NB All sales growth numbers in LC unless specified otherwise. Growth was solely driven by diabetes and obesity (+6%) sales of DKK23.37bn, making up for the flat performance of the biopharma business to DKK4.40bn. There was no respite for insulins (-2%) during the quarter, with the pressure i